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Aim: the surgical workup for colorectal cancer peritoneal metastases (CRCPM) is complex and should be
managed in specialized centers. Diagnostic and therapeutic algorithms (DTA) have been proposed to
balance optimal patients management and correct use of resources. Aim of this study was to establish a
consensus on DTA for CRCPM patients in Italy.
Method: a panel of 18 delegated members of centers afferent to Peritoneal Surface Malignancies Onco-
team of the Italian Society of Surgical Oncology was established. A list of statements regarding the DTA of
patients with CRCPM was prepared according to different activities and decision-making nodes with a
defined entry and exit point. Consensus was obtained through RAND UCLA methodology.
Results: two different DTA were defined and approved according to the modality of presentation of
CRCPM (synchronous and metachronous). A consensus was also obtained on 17 of the 19 statements
related to DTA.
Conclusion: a shared model of DTA is now available for healthcare providers to monitor appropriateness
in diagnosis and treatment of patients with isolated peritoneal metastases from CRC.
© 2020 Published by Elsevier Ltd.ncies Unit, Fondazione IRCCS
Milan, Italy.
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Colorectal cancer (CRC) represents the third most commonal., Diagnostic and therapeutic algorithm for colorectal peritoneal
am of the Italian society of surgical oncology, European Journal of
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[1]. During the last decade, the median overall survival for patients
with CRC metastatic disease have improved significantly and is
currently estimated around 30 months [2]. Although peritoneum is
a rare site of CRC spread (4.8e8.3%) [3e5], peritoneal metastases
(PM) are associated with the worst prognosis compared to other
metastatic sites (liver, lung, lymph nodes), with a median overall
survival of 16,3 months [6]. Systemic chemotherapy, alone or
combination with targeted therapy, represents a standardized
approach of CRCPM [7,8]. In selected patients, cytoreductive sur-
gery associated (CRS) followed by hyperthermic intraperitoneal
chemotherapy (HIPEC) has been shown to be effective in prolong-
ing survival compared to systemic treatment alone [9e12]. Patient
selection remains crucial to obtain satisfactory results after CRS-
HIPEC. Optimal cytoreduction with less than 2.5 mm (so called
cytoreduction grade 0 or 1) and limited tumor diffusion inside the
peritoneal cavity (expressed by the peritoneal cancer index, PCI)
represent the most important prognostic factors for recurrence and
survival in CRCPM treated with CRS-HIPEC [13,14].
Health requirements of the oncologic population becomes more
and more complex every. In this scenario, diagnostic and thera-
peutic algorithms (DTA) allowing the definition of the most viable
path within a single organization and network [15] for a particular
disease or clinical problem are crucial. In this perspective, a defined
DTA for CRCPM is needed for several reasons [16]. Most CRCPM
patients are diagnosed outside a tertiary referral center, frequently
in an emergency setting. When PM are discovered by colorectal
surgeons during abdominal exploration, surgical strategy is neither
clear nor standardized [17]. It is possible that a significant number
of patients with peritoneal disease who may benefit from a
multimodal approach such as CRS-HIPEC are undertreated, and
every effort should be made to define the best clinical pathway for
diagnosis and treatment of this group of patients. Moreover, CRS-
HIPEC is a very complex procedure that is available in a limited
number of specialized centers. Evaluation of CRCPM patients in
these centers allows to select those who would benefit more from
surgery in terms of morbidity and mortality, therefore optimizing
the costs of treatment and improving patient quality of life [18,19].
Aim of this study is to establish a consensus on a DTA model
viable for CRCPM patients.
Method
The consensus panel included 18 delegated members of centers
afferent to Peritoneal Surface Malignancies Onco-team of the Ital-
ian Society of Surgical Oncology. The steering committee was
charged of constructing a DTA considering the best evidence-based
treatment options for CRCPM. During a first meeting (Siena, May 17,
2019), after widespread review of national or society guidelines and
results of randomized controlled trials, phase I and II clinical
studies, the committee determined that low quality evidence data
were of little help to drive decision making. Thus, consensus on list
of statements, based on the available literature and expert opinion,
and appropriate to create a DTA for CRCPM was designed. DTA was
diagrammed into a pathwaywhich covers CRCPM patient care from
the initial diagnosis through curative and palliative treatments.
DTA was divided in two main clinical scenarios (synchronous and
metachronous CRCPM) and organized according to different ac-
tivities and decision-making nodes with a defined entry and exit
point. A list of 19 statements regarding the different activities and
decision-making nodes of the DTA were discussed and modified
during a second meeting (Cagliari September 9, 2019). Definitive
achievement of consensus was obtained through the RAND/Uni-
versity of California Los Angeles Appropriateness Methodology
[20]. Appropriateness was scored from 1 (inappropriate) to 92
(completely appropriate). For each statement the appropriateness
median score (AMS) was calculated. Statements were classified into
three levels of appropriateness: appropriate (AMS, in range 7e9),
uncertain (AMS, in range 4e6)) and inappropriate (AMS, in range
1e3). Agreement among panellists on each statement was estab-
lished according to an Interpercentile Range (IPR) of 0,3-0,7. If the
IPR obtained was in range 7e9, this was considered indicative of
agreement for that statement. Each panellist ranked anonymously
via web each statement for appropriateness as reported above. The
samemethod has been used for obtaining consensus of the diagram
of DTA. Statistical analyses (median and IPR) were conducted with
SPSS 17.0 (SPSS Statistics, Release 17.0.0).
Results
The statements were related to different decision-making points
in the clinical algorithm of CRCPM patients: 7 (1e7) the manage-
ment of patients diagnosed with synchronous disease, 7 the
multidisciplinary evaluation (8e14), 1 (15) the HIPEC regimen, 4
the role of perioperative systemic chemotherapy (16e19) (Table 1).
All the statements proposed for consensus were considered
appropriate with an AMS ranging between 7 and 9. Statements 14
and 19, although scored as appropriate (AMS 7,5 and 7 respectively)
didn’t reach consensus with an IPR lower than limit of 7 (both 6).
Statement 13 obtained an AMS of 7 but the IPR was 7e8. The voting
results on statements are summarized in Table 2.
The two DTA diagrams for synchronous (Fig. 1) and metachro-
nous CRCPM (Fig. 2) obtained both an APM of 9 and an IPR of 8e9.
Discussion
The current study reports on a consensus obtained for a DTA in
CRCPM patients. In oncology, DTA represents an organizational
health pathway, distinct for specific tumors and stages, in which
every step of the process is codified and the responsibility for its
execution and implementation are clear and defined. The main
objectives of DTA is to provide timely patient management, quality
of care and patient satisfaction, continuity and equity in terms of
access of care and an optimal use of resources. CRCPM is a typical
clinical situation in where the complexity of the diagnostic and
therapeutic process determines circumstances favouring the het-
erogeneity of care and facilitate inappropriate behaviors and/or
errors, thus causing adverse effects on cancer prognosis and an
increase in treatment costs [18,19]. In a Dutch population study, a
large variation in treatment approach for synchronous CRCPM was
observed at individual hospital level (teaching versus non-teaching
center), with significant differences in the chance to undergo CRS-
HIPEC and to obtain a favorable survival outcome [21].
The consensus was reached for two main clinical situations,
synchronous and metachronous CRCPM (Figs. 1 and 2). In around
10% of cases, PM occur at the time of primary presentation (syn-
chronous) [3,5]. If primary tumor is asymptomatic/uncomplicated,
patients with suspected synchronous peritoneal involvement
should be directly evaluated by a peritoneal tumor referral center
(PTRC) and considered for curative CRS [22] (statement 1). How-
ever, PM are more difficult to be detected by conventional imaging
(CT or MRI scan) compared to other metastatic sites (liver, lung and
lymph nodes) and PM can be an unexpected event (around 4%)
during surgery for primary CRC [4]. Intra-operative diagnosis of PM
during treatment of primary CRC occurs in most of cases in non-
specialized centers. The correct strategy in this situation is still
matter of debate. Small retrospective studies showed that the 5-
year overall survival of patients treated with surgical resection of
the primary and synchronous PM is about 30%, which is lower than








1 9 yes 8,1-9 valid
2 8 yes 8e9 valid
3 9 yes 9e9 valid
4 8 yes 7e9 valid
5 8 yes 7,1e8,9 valid
6 9 yes 8,1-9 valid
7 9 yes 9e9 valid
8 9 yes 9e9 valid
9 8,5 yes 8e9 valid
10 8 yes 7e9 valid
11 9 yes 8e9 valid
12 9 yes 8e9 valid
13 7 yes 7e8 valid
14 7,5 yes 6e9 not valid
15 8 yes 8e9 valid
16 8 yes 7,1-9 valid
17 8 yes 8e9 valid
18 8 yes 7,1e8,9 valid
19 7 yes 6e8 not valid
Table 1
Selected statements for consensus.
1 Patients with suspected synchronous peritoneal metastases should be directly evaluated by a peritoneal tumor referral center if the primary is asymptomatic/
uncomplicated
2 PM can be an unexpected event during surgery for primary CRC. In this case, if the nodules are limited and close to the tumor, resection of the primary and the
peritoneum involved, it is an acceptable option. However, one-stage curative treatment with HIPEC in referral centers is preferable whenever possible
3 PM can be an unexpected event during surgery for primary CRC. If the tumor load is high, with multiple and diffuse nodules, a simple histological confirmation and an
accurate intra-operative staging (PCI and unresectability causes) is the best choice, before sending the patient to a peritoneal referral center
4 If the patient is symptomatic and peritoneal metastases is suspected, surgery should be performed according to the urgency to intervene before sending the patient to a
peritoneal referral center
5 In case of obstruction, perforation or bleeding, when radical resection of the primary can be carried out safely and limited nodules are present, resection of the primary
combined with peritoneal metastases is an acceptable option before sending the patient to a peritoneal referral center
6 When surgery is emergent and peritoneal metastases are diffuse, a limited palliation (primary resection only, stoma formation) with peritoneal biopsy and staging (PCI
and unresectability causes) are indicated, before sending the patient to a peritoneal referral center
7 Every patient potentially eligible for CRS-HIPEC should be evaluated by a referral centre and discussed in dedicated colorectal multidisciplinary meetings
8 During colorectal multidisciplinary meetings a complete medical history, abdominal/thoracic CT scan and blood tumor markers should be available
9 CT scan with contrast enhancement medium represents the gold standard for stage patients with colorectal peritoneal metastases
10 MRI and PET scan should be considered complementary imaging for stage patients with colorectal peritoneal metastases
11 Laparoscopy is a complementarymethod for stage patients with colorectal peritoneal metastases and It is crucial that is performed by surgeons with experience in CRS-
HIPEC
12 Only patients with pre-operative Peritoneal Cancer Index <16 and with the possibility of obtain a CC0/1 resection should be selected for CRS-HIPEC
13 Molecular gene mutation testing (RAF/RAS mutation) and microsatellite status (stable or not) are important selection factors for CRS-HIPEC
14 Performance status, extraperitoneal metastases (liver, lymph nodes), tumor site (right versus left colon) tumor differentiation, signet ring histology, ascites, symptoms
of obstruction and lymph node status (N2a) of the primary in case of metachronous PM should be carefully considered potentially exclusion criteria for CRS-HIPEC
15 In patients selected for CRS-HIPEC Mitomycin C based regimen is recommended
16 Before selecting patients to CRS-HIPEC pre-operative chemotherapy should be always considered especially in presence of synchronous disease
17 Peritoneal progression during systemic chemotherapy should not be considered an absolute contraindication for CRS-HIPEC, if the selection criteria are still met
18 In very selected patients with limited metachronous peritoneal metastases and no risk factors, perioperative systemic chemotherapy could be omitted in favour of a
front-line CRS-HIPEC
19 In the sub-group of patients with peritoneal metastases who have mismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI-H), the treatment
with immune checkpoint inhibitor should be considered as first choice
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seems to determine extended bowel resections and permanent
colostomy respect to patients treated with a one-stage procedure
[25]. Even if, one stage curative in PTRC is preferable, in presence of
nodules limited and close to the tumor, resection of the primary
and the peritoneum involved, it is an acceptable option (statement
2) [26,27]. Patients treated for synchronous PM in non-specialized
centers, even thosewith complete resection, should be referred to a
PTRC. In a significant quote of patients who underwent resection of
PM at the time of primary treatment, a second look surgery allows
to discover and treat further peritoneal metastatic nodules with
similar outcomes of one-stage curative treatment [28,29]. If the
tumor load is high, with multiple and diffuse nodules, a simple
histological confirmation after an accurate intra-operative staging3
(PCI and unresectability causes) is the best choice, before sending
the patient to a PTRC (statement 3). In patients with suspected
CRCPM and symptoms of obstruction/bleeding, emergency surgery
should be performed (statement 4). In case of not deferred surgery
for perforation, obstruction or bleeding, radical resection of the
primary can be carried out if safe and limited nodules are present,
(statement 5). However, in case of emergency surgery and diffuse
PM, a limited palliation (primary resection only, stoma formation)
with peritoneal biopsy and staging (PCI and unresectability causes)
is the best option (statement 6). In those patients treated in an
emergency setting but still bearing PM, a procedure of CRS-HIPEC
remains a valuable and safe option with a 5-year survival rate
similar to that of elective cases [30]. One-stage curative treatment
at HIPEC referral centers is still the preferred choice whenever
possible [28] and every patient with synchronous PM potentially
eligible for CRS-HIPEC should be evaluated by a referral center and
discussed in dedicated CRC multidisciplinary meetings (statement
7).
After primary curative treatment, the rate of metachronous PM
can reach 19% of cases [31]. Multidisciplinary discussion of CRCPM
patients is mandatory for selecting the best therapeutic approach.
In this setting, a complete medical history, abdominal/thoracic CT
scan and blood tumor markers should be available (statement 8).
Every patient with a diagnosis of CRC should undergo CT scan with
contrast enhancement mediumwhich represents the gold standard
not only for diagnosis but also for staging thosewith PM (statement
9). Sensitivity and specificity of CT scan in CRCPM is estimated 83
and 86%, respectively [32]. The diagnostic performance of CT scan
for PM is dependent on the radiologist’s experience and can be
suspected in presence of defined radiological features (ascites, or-
gan invasion) [33]. The role of MRI and PET-CT as complementary
investigations are still under investigation and should be reserved
in selected cases and performed by experienced radiologists in PM
diagnosis (statement 10) [32]. Diffusion-weighted MRI is promising
for estimation of PCI and prediction of operability but its role is still
under study [34,35]. Laparoscopic exploration is an important tool
Fig. 1. Diagnostic and therapeutic pathway for synchronous CRCPM.
Fig. 2. Diagnostic and therapeutic pathway for metachronous CRCPM.
A. Sommariva, L. Ansaloni, G.L. Baiocchi et al. European Journal of Surgical Oncology xxx (xxxx) xxx
4
A. Sommariva, L. Ansaloni, G.L. Baiocchi et al. European Journal of Surgical Oncology xxx (xxxx) xxxfor confirming the diagnosis of peritoneal involvement, allowing a
histological definition of all suspected nodules [29]. Laparoscopic
exploration can assess the peritoneal cancer index (PCI) more
accurately then preoperative radiological investigations [36].
Moreover, during laparoscopy, any potential cause of unresect-
ability (mesenteric retraction or infiltration of the hepatic hilum,
suprahepatic veins and Treitz ligament) can be easily identified
under direct vision [37]. Therefore, it is crucial that laparoscopy
should be performed by skilled surgeons in peritoneal surgery, it
being is the most accurate staging tool in patients selected for
surgery (statement 11).
Despite notable advances in systemic treatments, patients with
isolated PM treated only with cytotoxic/targeted agents show a
significantly worse survival (16,3 months) as compared to patients
with isolated non-peritoneal sites (liver, lung, lymph nodes) [6].
CRS-HIPEC allows to provide a long-term survival of up to 40
months in selected patients treated in PTRC and is widely adopted
worldwide and included in several national guidelines [38e42].
However, the real added value of HIPEC over CRS alone is still under
investigation. A recent French multi-institutional randomized
controlled trial (Prodige 7) presented at the ASCO annual meeting
confirms the relevant role of surgery to treat patients with PM but
was not able to show any survival advantage in adding HIPEC to
radical surgery [24]. The study is not yet published and it is difficult
to assess all aspects and bias, but an important point is that in the
subgroup analysis of patients with PCI less than 16, overall survival
is significantly better in the HIPEC arm, confirming previous results
on the impact of this benchmark in patient prognosis [43]. There-
fore, only patients with PCI <16 inwhich a complete surgery can be
obtained (grade of cytoreduction or residual disease zero or less
than 2,5 mm) (statement 12).
The role of additional selection factors and their weight within
the pre-operative evaluation is unclear and also the panelist didn’t
reach a consensus on this point. Among these, mutations in the RAS
and RAF pathway have a detrimental effect on prognosis but a clear
link to peritoneal progression has not yet been clearly demon-
strated [44]. However, the selection process for CRS-HIPEC should
include always a molecular gene mutation testing (RAS/RAF mu-
tation) and microsatellite status (stable or not) which should be
considered important selection factors (statement 13). Other se-
lection factors as performance status (Eastern Cooperative
Oncology Group, ECOG), extraperitoneal metastases (liver, lymph
nodes), tumor site (right versus left colon) tumor differentiation
and signet ring histology ascites, symptoms of obstruction and
lymph node status (N2a) of the primary [45], are not considered
crucial in the selection process (statement 14).
According to the results of the Prodige 7 trial which showed no
survival advantage andmore complications (bleeding) in the arm of
patients treated with an oxaliplatin based HIPEC, the panelists
recommended a Mitomycin C based regimen in patients treated
with maximal cytoreduction surgery [24] (statements 15), which is
also the most used protocol in Italy. This is in accordance with
previous comparative studies which are unable to show any su-
periority in terms of oncological efficacy of one drug over the other.
However, some evidence showed that Oxaliplatin in HIPEC
schedule is clearly associated with a worse side effects profile
[46,47].
The role of perioperative chemotherapy in eligible patients for
CRS-HIPEC is controversial and this topic is still under study
[48e51]. A randomized controlled study (CAIRO 6) addressing the
role of perioperative systemic chemotherapy (SC) for patients with
isolated and resectable CRCPM is ongoing in the Netherlands [52].
After CRS-HIPEC, systemic failure is a relatively common event [53],
and postoperative SC can lead to better peritoneal tumor control by
eradicating non-visible cells as supposed for lung and liver5
metastatic patients treated by potentially curative resection [54]. SC
after surgery should be indicated according to the recognized risk
factors of postoperative recurrence [45]. Before CRS-HIPEC, SC
should be considered in all patients with CRCPM (especially syn-
chronous) according to the protocols proposed for metastatic CRC
(statement 16). Although a relative unresponsiveness of CRC peri-
toneal nodules to SC is demonstrated (response rate around
10e20% lower than those reported for liver metastases) [55], SC
should be considered for several reasons, especially in presence of
synchronous disease. SC can reduce peritoneal tumor load,
improving the chance of achieving complete cytoreduction by tu-
mor downsizing and performing a less extensive surgery with
lower morbidity [55]. Another theoretical advantage of “neo-
adjuvant” chemotherapy is that it allows a better selection of pa-
tients, by excluding from surgery those who develop early distant
progression (liver, lung, lymph nodes). Isolated peritoneal pro-
gression during systemic CHT should not be considered an absolute
contraindication for CRS-HIPEC, if the other selection criteria are
still met [56] (statement 17). In very selected patients with limited
metachronous PM and no risk factors, perioperative systemic CHT
could be omitted after MDT discussion in favour of a front-line CRS-
HIPEC (statement 18). In the sub-group of CRCPM patients who
have mismatch repair-deficient (dMMR) and/or microsatellite
instability-high (MSI-H), the treatment with immune checkpoint
inhibitor is considered a promising option, also as first choice
treatment [57]. However, the role of immunotherapy in CRCPM is
still under study and although deemed appropriate, should not
considered as preferable treatment over CRS-HIPEC if the selection
criteria are meet (statement 19).
There is an increasing interest for quality and standardization in
surgery, especially in complex procedures requiring specific pro-
fessional skills which must be consistent at the different levels and
steps of care and be delivered in a coordinatedmanner to obtain the
best results [58,59]. Our study has defined a shared algorithm for
diagnosis and treatment in a very challenging clinical situation as
the occurrence of CRCPM. Additional efforts should be made in this
field considering that, for example, no defined criteria are available
in most countries and health care systems for the identification of a
PTRC. The learning curve is a crucial point to identify centers able to
cure these patients with high quality and efficacy. Indeed, the
number of procedures performed remains the most objective
parameter related to post-operative outcomes (mortality, compli-
cations) and oncological results (incomplete cytoreduction, early
recurrence) [60,61]. Moreover, further studies will be necessary,
which measure the appropriateness and quality of the care path of
CRCPM patients through proper QA indicators (relevant, reliable,
valid and easily useable), with the primary goal of ameliorating
outcomes (survival/quality of life) and cost of treatments of these
patients.
Conclusion
A consensus on DTA for CRCPM patients have been reached in
Italy. The document will be an important tool for healthcare pro-
viders to monitor appropriateness in diagnosis and treatment of
CRC patients with isolated peritoneal metastases.
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